Biologics and Psoriasis The Beat Goes On

被引：40

作者：

Kim, Hee J. ^{[1
]}

Lebwohl, Mark G. ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 East 98th St,5th Floor,POB 1048, New York, NY 10029 USA

来源：

DERMATOLOGIC CLINICS | 2019年 / 37卷 / 01期

关键词：

Biologics; Psoriasis; Psoriatic arthritis; Efficacy; Safety; Th17/IL-23; axis; TO-SEVERE PSORIASIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; PLAQUE PSORIASIS; DOUBLE-BLIND; PHASE-III; CONTROLLED-TRIAL; MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS; SAFETY; EFFICACY;

D O I：

10.1016/j.det.2018.07.004

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

引用

页码：29 / +

页数：9

共 55 条

[11]

[Anonymous], 2016, TALTZ IX PACK INS

[12]

[Anonymous], 2018, ILUMYA TILDR ASMN PA

[13]

Bissonnette R, 2018, J EUR ACAD DERMATOL

[14] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) [J].

Blauvelt, Andrew ;

Gooderham, Melinda ;

Iversen, Lars ;

Ball, Susan ;

Zhang, Lu ;

Agada, Noah O. ;

Reich, Kristian .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) :855-862

[15] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].

Blauvelt, Andrew ;

Papp, Kim A. ;

Griffiths, Christopher E. M. ;

Randazzo, Bruce ;

Wasfi, Yasmine ;

Shen, Yaung-Kaung ;

Li, Shu ;

Kimball, Alexa B. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417

[16] Safety of secukinumab in the treatment of psoriasis [J].

Blauvelt, Andrew .

EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) :1413-1420

[17] Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease [J].

Burmester, Gerd R. ;

Panaccione, Remo ;

Gordon, Kenneth B. ;

McIlraith, Melissa J. ;

Lacerda, Ana P. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (04) :517-524

[18] Safety of dermatologic medications in pregnancy and lactation Part II. Lactation [J].

Butler, Daniel C. ;

Heller, Misha M. ;

Murase, Jenny E. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (03) :426-+

[19] Immunity to infection in IL-17-deficient mice and humans [J].

Cypowyj, Sophie ;

Picard, Capucine ;

Marodi, Laszlo ;

Casanova, Jean-Laurent ;

Puel, Anne .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (09) :2246-2254

[20] Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy -: Results from the British Society for Rheumatology Biologics Register [J].

Dixon, W. G. ;

Watson, K. D. ;

Lunt, M. ;

Silman, A. J. ;

Hyrich, K. L. ;

Symmons, D. P. M. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :2905-2912

← 1 2 3 4 5 6 →